Absci (NASDAQ: ABSI) — Company Overview, News & Financial Data
Absci leverages synthetic biology and AI to accelerate drug discovery and production, aiming for better therapeutics and reduced costs.
Absci
Absci (NASDAQ:ABSI) specializes in harnessing the power of synthetic biology to dramatically accelerate drug discovery and development. By integrating artificial intelligence and advanced biological techniques, the company works to revolutionize how proteins are produced and engineered, aiming to bring new, better therapeutics to market faster. Absci's projects primarily focus on creating highly-efficient, cost-effective drug production platforms that can significantly shorten the development time from concept to clinical trials. The company's overarching objective is to become a pivotal player in the biopharmaceutical industry by enabling the creation of novel medicines with their cutting-edge technology, ultimately improving patient outcomes and reducing healthcare costs.
Snapshot
Operations
Products and/or services of Absci
- Integrated Drug Creation™ platform, leveraging AI and synthetic biology for accelerating drug discovery and development.
- E. coli production strain for manufacturing complex biologics, enhancing effectiveness and reducing production costs.
- Solubilized Membrane Protein technology, enabling the discovery of antibodies for previously intractable targets.
- Cell Line Development services, offering rapid and efficient generation of high-yielding cell lines for biomanufacturing.
- Bionic Protein™ technology, incorporating non-standard amino acids into proteins for creating enhanced therapeutics.
- AI-driven Drug Design and Protein Screening platforms, streamlining the identification and optimization of novel drug candidates.
Absci executive team
- Sean McClainFounder, CEO, President & Director
- Zachariah JonassonChief Business Officer & CFO
- Todd BedrickSenior VP & Chief Accounting Officer
- Alexander KhanCVP of Finance & Head of Investor Relations
- Shelby WalkerChief Legal Officer
- Jeanne SchreuderSenior Vice President of People & Experience
- Wen ShaChief of Staff
- Christine LemkeSenior Vice President of Portfolio & Growth Strategy
- Ransi SomaratneChief Medical Officer
- Moetaz B. AlbizemSenior Vice President of Clinical Operations
Latest news about Absci
Key financials
Reported results for Absci , in USD.
- Market cap
- 1.7B
- Revenue (TTM)
- 1.6M
- P/E ratio
- —
- EPS (diluted, TTM)
- -0.8
- Dividend yield
- —
- Profit margin
- 0.0%
| Fiscal year end | Revenue | Operating income | Net income |
|---|---|---|---|
| 2.8M | -124.7M | -115.2M | |
| 4.5M | -108.9M | -103.1M | |
| 5.7M | -115.5M | -110.6M | |
| 5.7M | -106.8M | -104.9M |